Discover IMRX’s innovative cancer drug atebimetinib and upcoming milestones. Learn about trial results, financial outlook, ...

Bottom line: The MEK inhibitor trametinib (Mekinist) was an effective treatment for pediatric patients with relapsed or refractory juvenile myelomonocytic leukemia (JMML) enrolled in a phase II ...

Pasithea Therapeutics announced promising preclinical data for PAS-004, a next-generation MEK inhibitor, which shows superior effectiveness in inhibiting the ETS2 pathway associated with ...

Radiosurgery as primary treatment of metastatic tumors of the spine: Quality of life and adjuvant surgical approach after Cyberknife. Background: AZD6244 is a second generation MEK inhibitor that ...

Kinnate Biopharma Inc. has added two new internally developed next-generation development candidates to its targeted oncology pipeline, a brain-penetrant mitogen-activated protein kinase kinase (MEK) ...

Almost half of adults and children with neurofibromatosis type 1 (NF1) responded to the investigational MEK inhibitor mirdametinib, a large multicenter study of the rare condition showed. Overall, 53 ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SEOUL, South ...

This month, our discussion focuses on the clinical management of plexiform neurofibromas in the era of selumetinib, a MEK inhibitor medication that was approved by the FDA in 2020 for the treatment of ...

Pasithea Therapeutics Corp. has received IND clearance by the FDA to evaluate PAS-004, a small-molecule allosteric inhibitor of MEK 1/2, in patients with MAPK pathway-driven advanced solid tumors with ...